Arthritis is a group of inflammatory joint disorders causing pain, swelling, and stiffness. The most common types include osteoarthritis, a degenerative condition affecting joint cartilage, and rheumatoid arthritis, an autoimmune disease causing joint inflammation. Other variants such as gout, lupus, and ankylosing spondylitis exist, each with distinct characteristics. Arthritis can affect people of all ages, hindering mobility and reducing quality of life. Effective management involves medication, lifestyle adjustments, and sometimes surgery to alleviate symptoms and improve joint function.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/us-arthritis-market
Data Bridge Market Research analyses that the U.S. Arthritis Market is growing with a CAGR of 10.2% in the forecast period of 2022 to 2029 and is expected to reach USD 78,400.47 million by 2029 from USD 36,046.73 million in 2021. The healthcare landscape is evolving towards patient-centric models, emphasizing personalized arthritis management. This shift drives demand for diverse treatment options, ensuring tailored care plans to enhance patient outcomes and satisfaction.
Key Findings of the Study
Rising healthcare expenditure is expected to drive the market's growth rate
The escalating healthcare expenditure in the U.S. plays a pivotal role in expanding access to arthritis treatments, propelling market growth. With increased financial resources allocated to healthcare, individuals gain enhanced accessibility to advanced therapies, medications, and surgical interventions for arthritis. This financial support benefits patients by improving their treatment options and stimulates innovation and research in the arthritis sector, leading to the development of more effective and cutting-edge solutions for this prevalent health concern.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Spondyloarthritis, Juvenile Idiopathic Arthritis (JIA), and Others), Product (Treatment and Diagnosis), Drug Type (Branded and Generics), Medication Type (Prescription Drugs and Over-The-Counter Drugs), Route of Administration (Parenteral, Oral and Others), Population Type (Geriatrics, Adults and Children), End User (Hospital, Specialty Centers, Homecare and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Market Players Covered
|
AbbVie Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Amgen Inc. (U.S.), F. Hoffman-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (U.S.), UCB S.A. (Belgium), Sanofi (France), Flexion Therapeutics Inc. (U.S.), Celltrion Healthcare Co., Ltd. (South Korea), Swedish Orphan Biovitrum AB (Sobi) (Sweden), Bio-Rad Laboratories, Inc. (U.S.), Anika Therapeutics, Inc. (U.S.), Siemens Healthcare GmbH (Germany), Thermo Fisher Scientific Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Bayer AG (Germany), Abbott (U.S.), Apotex Inc. (Canada), Samsung Bioepis (A Subsidiary of Samsung Biologics) (South Korea), Beckman Coulter Inc. (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The U.S. arthritis market is segmented into type, product, drug type, medication type, route of administration, population type, end user, and distribution channel.
- On the basis of type, the U.S. arthritis market is segmented into rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, spondyloarthritis, juvenile idiopathic arthritis (JIA), and others
- On the basis of product, the U.S. arthritis market is segmented into treatment and diagnosis
- On the basis of drug type, the U.S. arthritis market is segmented into branded and generics
- On the basis of medication type, the U.S. arthritis market is segmented into prescription drugs and over-the-counter drugs
- On the basis of route of administration, the U.S. arthritis market is segmented into parenteral, oral, and others
- On the basis of population type, the U.S. arthritis market is segmented into geriatrics, adults, and children
- On the basis of end user, the U.S. arthritis market is segmented into hospitals, specialty centers, homecare, and others
- On the basis of distribution channel, the U.S. arthritis market is segmented into direct tender, retail sales, and others
Major Players
Data Bridge Market Research recognizes the following companies as the major U.S. arthritis market players in U.S. arthritis market are AbbVie Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Amgen Inc. (U.S.), F. Hoffman-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (U.S.), UCB S.A. (Belgium), Sanofi (France)
Market Developments
- In February 2023, Roche expanded collaboration with Janssen Biotech Inc., aiming to develop companion diagnostics for targeted therapies. This strategic alliance enhances research and innovation in the arthritis market, fostering the creation of more precise diagnostic tools. The collaboration signifies a commitment to advancing personalized treatments, potentially revolutionizing arthritis care and contributing to the evolution of tailored therapeutic approaches
- In December 2022, Merck KGaA initiated a research collaboration and commercial license pact with Mersana Therapeutics, Inc. This strategic partnership aims to explore groundbreaking antibody-drug conjugates (A.D.C.s) using Mersana's proprietary Immunosynthen STING-agonist A.D.C. platform. This collaboration, focusing on up to two targets, holds potential for innovative therapeutic solutions in the arthritis market, marking a significant step toward advancing treatment options for arthritis patients
- In September 2022, Alkem Laboratories secured regulatory approval from the Drug Controller General of India for StemOne, an off-the-shelf cell therapy. Developed in collaboration with Stempeutics, the product targets knee osteoarthritis, aligning with the arthritis market's growing demand for innovative treatments. This regulatory milestone underscores advancements in arthritis therapies, potentially reshaping the landscape and offering new avenues for addressing degenerative joint diseases in India
- In January 2022, AbbVie's announcement of the FDA approval for SKYRIZI (risankizumab-rzaa) to treat active psoriatic arthritis significantly supported the company's revenue. This breakthrough addresses a critical need for the 30% of psoriatic arthritis patients impacted by the systemic inflammatory disease affecting skin and joints. The approval underscores AbbVie's commitment to advancing effective therapies and expands its market presence, contributing to increased financial success
- In December 2021, AbbVie Inc. secured FDA approval for RINVOQ (upadacitinib) to treat active psoriatic arthritis, contributing to the company's revenue surge and product portfolio expansion. This regulatory milestone enhances AbbVie's market presence, offering a new therapeutic option for individuals with psoriatic arthritis and reinforcing the company's commitment to advancing innovative solutions in the field of rheumatology
- In July 2020, Johnson & Johnson Services, Inc. achieved FDA approval for the use of TREMFYA in treating psoriatic arthritis. This milestone significantly strengthened the company's global presence and diversified its product portfolio. The approval underscores Johnson & Johnson's commitment to advancing innovative solutions, providing patients with a new and effective option for managing psoriatic arthritis, ultimately contributing to the company's growth
For more detailed information about the U.S. arthritis market report, click here – https://www.databridgemarketresearch.com/jp/reports/us-arthritis-market
